EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins

Laetitia Misson Mindrebo iD, Hejun Liu iD, Gabriel Ozorowski iD, Quoc Tran iD, Jordan Woehl iD, Irene Khalek, Jessica M Smith iD, Shawn Barman, Fangzhu Zhao iD, Celina Keating, Oliver Limbo iD, Megan Verma iD und 10 weitere

Proceedings of the National Academy of Sciences · 13.06.2023 · 120 (24)

DOI: 10.1073/pnas.2216612120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 05.06.2023. Verfasst von Laetitia Misson Mindrebo und 21 weiteren Autor:innen. Beteiligte Einrichtung: International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037. Hauptthemen laut MEDLINE: Single-Domain Antibodies, COVID-19. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIGMS NIH HHS, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanobodies bind a target antigen with a kinetic profile similar to a conventional antibody, but exist as a single heavy chain domain that can be readily multimerized to engage antigen via multiple interactions. Presently, most nanobodies are produced by immunizing camelids; however, platforms for animal-free production are growing in popularity. Here, we describe the development of a fully synthetic nanobody library based on an engineered human V H 3-23 variable gene and a multispecific antibody-like format designed for biparatopic target engagement. To validate our library, we selected nanobodies against the SARS-CoV-2 receptor–binding domain and employed an on-yeast epitope binning strategy to rapidly map the specificities of the selected nanobodies. We then generated antibody-like molecules by replacing the V H and V L domains of a conventional antibody with two different nanobodies, designed as a molecular clamp to engage the receptor-binding domain biparatopically. The resulting bispecific tetra-nanobody immunoglobulins neutralized diverse SARS-CoV-2 variants with potencies similar to antibodies isolated from convalescent donors. Subsequent biochemical analyses confirmed the accuracy of the on-yeast epitope binning and structures of both individual nanobodies, and a tetra-nanobody immunoglobulin revealed that the intended mode of interaction had been achieved. This overall workflow is applicable to nearly any protein target and provides a blueprint for a modular workflow for the development of multispecific molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesCOVID-19HumansSaccharomyces cerevisiaeSARS-CoV-2AntibodiesEpitopes

Stichwörter der Autor:innen

SARS-CoV-2 neutralizationbispecific antibodynanobodysynthetic library

Substanzen

Single-Domain AntibodiesAntibodiesEpitopes

Autor:innen und Institutionen

  • International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037.
  • International AIDS Vaccine Initiative, New York, NY 10004.
  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.
  • Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037.
  • Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
  • Department of Bioengineering, Stanford University, Stanford, CA 94305.

ORCID-Profile: Laetitia Misson Mindrebo, Hejun Liu, Gabriel Ozorowski, Quoc Tran, Jordan Woehl, Jessica M Smith, Fangzhu Zhao, Oliver Limbo, Megan Verma, Jingjia Liu, Robyn L Stanfield, Xueyong Zhu, Po-Ssu Huang, Dennis R Burton, Andrew B Ward, Ian A Wilson, Joseph G Jardine

Förderung

  • Wellcome Trust
  • NIGMS NIH HHS
  • Bill and Melinda Gates Foundation

Zitieren

APA

Misson Mindrebo, L., Liu, H., Ozorowski, G., Tran, Q., Woehl, J., Khalek, I., Smith, J. M., Barman, S., Zhao, F., Keating, C., Limbo, O., Verma, M., Liu, J., Stanfield, R. L., Zhu, X., Turner, H. L., Sok, D., Huang, P. S., Burton, D. R., …, & Jardine, J. G. (2023). Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins. Proceedings of the National Academy of Sciences, 120(24). https://doi.org/10.1073/pnas.2216612120

Vancouver

Misson Mindrebo L, Liu H, Ozorowski G, Tran Q, Woehl J, Khalek I, et al. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins. Proceedings of the National Academy of Sciences. 2023;120(24). doi:10.1073/pnas.2216612120

BibTeX
@article{MissonMindrebo2023,
  author = {Misson Mindrebo, Laetitia and Liu, Hejun and Ozorowski, Gabriel and Tran, Quoc and Woehl, Jordan and Khalek, Irene and Smith, Jessica M and Barman, Shawn and Zhao, Fangzhu and Keating, Celina and Limbo, Oliver and Verma, Megan and Liu, Jingjia and Stanfield, Robyn L and Zhu, Xueyong and Turner, Hannah L and Sok, Devin and Huang, Po-Ssu and Burton, Dennis R and Ward, Andrew B and Wilson, Ian A and Jardine, Joseph G},
  title = {Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {24},
  doi = {10.1073/pnas.2216612120}
}
Kostenlos starten →